NASDAQ$AKRO
Akero Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Akero Therapeutics reported Q2 2025 results with a net loss of $70.5M and an EPS of -$0.86.
Akero Therapeutics posted a Q2 2025 net loss of $70.5 million, or -$0.86 per share, driven by increased R&D spending for Phase 3 trials. The company ended the quarter with $1.086 billion in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028.
- Net loss for Q2 2025 was $70.5 million, compared to $56.0 million in Q2 2024.
- EPS was -$0.86, compared to -$0.81 in Q2 2024.
- R&D expenses increased to $69.3 million due to Phase 3 trial activities.
- Cash and marketable securities totaled $1.086 billion, providing runway into 2028.
Headline financials
Revenue & EPS history
Akero · Revenue · Quarterly
$0
Forward guidance
Akero expects to report preliminary results from the SYNCHRONY Real-World Phase 3 trial in the first half of 2026 and SYNCHRONY Histology results in the first half of 2027, with cash runway into 2028.
Tailwinds
- Preliminary SYNCHRONY Real-World results expected in 1H 2026.
- SYNCHRONY Histology readout anticipated in 1H 2027.
- Cash runway expected to last into 2028.
- Positive Phase 2b SYMMETRY results published in NEJM.
- EASL 2025 presentations reinforced EFX's antifibrotic potential.
Headwinds
- Continued operating losses driven by R&D investment.
- No current revenue generation from product sales.
- Dependency on clinical trial success for future growth.
- High costs for Phase 3 trials and manufacturing.
- Potential regulatory risks impacting trial timelines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q2 2025
-0.4%
Avg return
Earnings day
-1.8%
Avg return
5 days after
+1.5%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+18.4%
Q2 2022
Best reaction
-20.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.2% | +0.3% | +0.9% | |
| Q2 2025 | +0.1% | -4.2% | -11.3% | |
| Q1 2025 | +4.3% | -2.5% | +33.0% | |
| Q4 2024 | +2.9% | -5.4% | -8.8% | |
| Q3 2024 | -5.2% | -11.2% | -10.8% | |
| Q2 2024 | -3.0% | -4.2% | +6.2% | |
| Q1 2024 | -0.9% | +1.2% | +10.5% | |
| Q4 2023 | +2.1% | +12.0% | -7.3% | |
| Q3 2023 | +5.3% | — | — | |
| Q2 2023 | +6.2% | — | — | |
| Q1 2023 | +0.2% | — | — | |
| Q4 2022 | -4.1% | — | — | |
| Q3 2022 | -6.8% | — | — | |
| Q2 2022 | +18.4% | — | — | |
| Q1 2022 | -11.4% | — | — | |
| Q4 2021 | -1.9% | — | — | |
| Q3 2021 | +4.6% | — | — | |
| Q2 2021 | +1.0% | — | — | |
| Q1 2021 | +2.6% | — | — | |
| Q4 2020 | -1.1% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -0.9% | — | — | |
| Q1 2020 | +2.8% | — | — | |
| Q4 2019 | -20.9% | — | — | |
| Q3 2019 | -3.8% | — | — | |
| Q2 2019 | +1.3% | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro